Sponsored

Prescient Therapeutics (ASX:PTX) to progress deep cancer-treatment pipeline with capital raise

August 26, 2022 02:02 AM CEST | By Aditi Sarkar
 Prescient Therapeutics (ASX:PTX) to progress deep cancer-treatment pipeline with capital raise
Image source: © Ipopba | Megapixl.com

Highlights

  • Prescient intends to raise AU$8.0 million via a Share Purchase Plan (SPP)
  • Funds from the SPP will be used to develop the company’s pipeline of innovative cancer therapies and for general working capital.
  • New fully paid ordinary shares will be distributed at $0.175 apiece.

Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.

Funds raised from the SPP will be used for the following:

  • Clinical development of PTX-100 and PTX-200 targeted therapies
  • Progressing its innovative cell therapies, OmniCAR and CellPryme-M, towards and into first-inhuman clinical studies
  • General working capital and expenses of the offer

Prescient Advancing New Cancer Therapies with A Leading Team of Global Cancer Specialists

*Eligible shareholders - Registered shareholders as at 5:00pm (AEST) on Tuesday 23rd August 2022 (Record Date).

Indicative timetable of key dates for the SPP

Payment deadline: 5pm (AEST) on Wednesday, 28 September 2022.

Commenting on the SPP, the company’s CEO & Managing Director, Steven Yatomi-Clarke said that Prescient is seeking to maintain the momentum and position in the oncology space gained by the company during the last few years. He further added that the company is working to develop a diverse and groundbreaking pipeline of personalised therapies for cancer.

For more on SPP

Shareholders can find more information on Prescient’s SPP by clicking here.

To know more about Prescient Therapeutics Limited, click here. Also, to stay updated with PTX company activities and announcements, please update your details on their investor centre.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles